Refractory AML Clinical Trials

17 clinical trials for Refractory AML across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT — RECRUITING · PHASE1
• A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML — RECRUITING · PHASE1
• CLL-1 CAR-NK Cells for Relapsed/Refractory AML — RECRUITING · PHASE1
• Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia — RECRUITING · PHASE2
• Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML — RECRUITING · PHASE1
• Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation — RECRUITING · PHASE2
• CART123 + Ruxolitinib in Relapsed/Refractory AML — ACTIVE_NOT_RECRUITING · PHASE1
• Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML — NOT_YET_RECRUITING · PHASE2
• Natural Killer Cell (CYNK-001) Infusions in Adults with AML — TERMINATED · PHASE1
• Tislelizumab with Azacitidine in the Treatment of R/R AML — WITHDRAWN · PHASE1
• Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia — WITHDRAWN · PHASE1
• Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) — OTHER · PHASE1
• An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia — OTHER · PHASE1
• A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE — COMPLETED
• Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia — TERMINATED · PHASE1
• Phase 1 Study of Quizartinib — COMPLETED · PHASE1

Refine this search